ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

episalvan

Also written as “Oleogel-S10”, “AP-101” and “Oleogel-S10, non-adhesive wound dressing”.

Its studies are mostly in Amyotrophic Lateral Sclerosis · Epidermolysis Bullosa · Wounds and Injuries · Epidermolysis Bullosa Dystrophica · Burns, led by 2 companies.

Drug pageEpisalvan: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 29, 201210 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chiesi Farmaceuticiits history only81 open or runningphase 3since Jul 29, 2012Nov 5, 2008none ahead
AL-S Pharma20 open or runningphase 2since Sep 1, 2021May 30, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AL-S Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 30, 2019First study: phase 1 study in Amyotrophic Lateral SclerosisFirst studyNCT03981536 · 18 enrolled · Canada
  2. Sep 1, 2021Phase 2 study in Amyotrophic Lateral SclerosisNCT05039099 · 73 enrolled · United States, Belgium, Canada and more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 AL-S Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05039099Amyotrophic Lateral Sclerosis · United States, Belgium, Canada and more2CompletedAug 13, 202573
NCT03981536Amyotrophic Lateral Sclerosis · Canada1UNKNOWNNov 2, 202018

How it is read

Names in the registry

  • “Oleogel-S10”, 4 entries
  • “AP-101”, 2 entries
  • “Oleogel-S10, non-adhesive wound dressing”, 2 entries
  • “Oleogel-S10 ointment”, 1 entry
  • “Oleogel-S10 100 mg/g”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.